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Identity 
Other names: BD1, DEFB-1, DEFB101, HBD1, 
MGC51822 
HGNC (Hugo): DEFB1 
Location: 8p23.1 
Local order: AGPAT5-XKR5-DEFB1-DEFA6-
DEFA4 (reverse strand, according to 
www.ensembl.org). 
Note: DEFB1 is a peptide expressed mainly in epithelia 
with an antimicrobial function against viruses, Gram-
positive, Gram-negative bacteria and Mycobacterium 
tuberculosis. It also functions as immunomodulator nd
as a tumor supressor gene. Single Nucleotide 
Polymorphisms (SNPs) in this gene have been 
associated with cancer, allergic and infectious diseases 
as well as with DEFB1 downregulation (Prado-Montes 




DEFB1 is a gene composed of 2 exons and a ~7 kb 
intron. DEFB1 spans 7488 bp, two exons and one 
intron of 6962 bp (Liu et al., 1997). 
Transcription 
The transcript is of 207 nt (www.kegg.org). No variants 
are produced by alternative splicing, the entire mature 
peptide coding sequence is in exon 1, however several 
hBD-1 amino-terminal processed forms are found in 
urine (Valore et al., 1998), probably cleaved by 
chymotrypsin (Zucht et al., 1998) or matrix 
metalloproteinase 7 (matrylisin) (Wilson et al., 2009) 
each showing different microbicidal potencies (Valore 
et al., 1998). The functions and tissue of origin of these 




Figure 1. DEFB1 gene. The diagram shows pre-propeptide coding sequence (black rectangles) and unstranslated regions (blue 
rectangles). Signal peptide coding sequence is comprised of 60 bases. Mature peptide coding sequence spans 144 bases 
(www.ensembl.org). The pro-peptide segment is in exon 1 and not in exon 2 as in the rest of beta-defensins known to date (Pazgier et 
al., 2006). 
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Figure 2. (A) Model of hBD-1 peptide (according to PDB:1IJU, www.pdb.org). (B) Sequence of hBD-1 pro-peptide. Signal peptide 
sequence (blue), mature peptide (black) with cysteine residues (bold) and disulfide bridges (brackets) are shown. 
 
Pseudogene 
None reported. DEFB1 is considered as a unique copy
gene, although rare duplicons in some individuals hve 
been reported (Linzmeier et al., 2005). 
Protein 
Note 
Human beta-defensins are produced mainly by various 
epithelia and secreted in mature forms by the producing 
cells. The hBD-1 shows three disulfide bridges (with 
the pro-peptide nomenclature) are formed at cysteines 
37-66 (1-5), 44-59 (2-4) and 49-67 (3-6). The disulf de 
bridge pattern on cysteines 1-5, 2-4 and 3-6 is a 
hallmark of beta-defensins (Prado-Montes de Oca, 
2010). 
Description 
The prepropeptide has 68 aa and the mature peptide is 
of 48 amino acids. As quaternary structure hBD-1 
shows in vitro dimerization by weak intermolecular s lt 
bridges, but if dimers are formed in vivo or if they 
perform any different function is unknown (Prado 
Montes de Oca, 2010). 
Expression 
The highest concentrations of hBD-1 are found in the 
kidney (epithelial layes of the loops of Henle, distal 
tubules, collecting tubes) and female reproductive tract 
(layers of vagina, ectocervix, endocervix, uterus, 
fallopian tubes), especially in pregnant women. It is 
also expressed in astrocytes, mammary gland, cornea, 
small intestine, gingival tissue, epithelial cells of testis, 
mature dendritic cells (for a more complete information 




The hBD-1 peptide resides in the cytoplasm of normal 
cells and in the nucleus of several cancer cells (Bick et 
al., 2007; Wenghoefer et al., 2008). In normal skin,  
hBD-1 is localized to the perinuclear region of 
keratinocytes and in burned skin in dermal glandular 
structures and hair shafts (Poindexter et al., 2006). 
Function 
hBD-1 functions as an antimicrobial peptide against 
viruses as HIV, Av1CF2, Gram-positive and Gram-
negative bacteria, Mycobacterium tuberculosis. It 
functions as a chemoattractant to immature dendritic 
cells and T cells acts as a tumor suppressor inducig 
caspase-mediated apoptosis. In addition it could be 
involved as transcription factor in epithelia 
reorganization (Prado Montes de Oca, 2010). 
Homology 
Homolog genes to human beta-defensin 1 are found in 
Mus musculus (mouse) (Morrison et al., 1998), Pan 
troglodytes (chimpanzee) (Prado-Montes de Oca et al., 
2009), Macaca mulatta (Rhesus monkey), Canis 
familiaris (dog), Rattus norvegicus (rat), Sus scrofa 
(pig, named beta defensin 2), Bos taurus (cow, named 




There are 214 annotated polymorphisms in DEFB1, 
most of them are SNPs (bdSNP build 130, 
www.genome.ucsc.edu). Insertions and deletions are 
less frequently found (López Campos and Prado 
Montes de Oca, in process). There are reports of 10 
SNPs in DEFB1 with disease association. The most 
relevant SNPs are those located on 5' unstranslated 
region namely -52A (higher HIV load and higher risk 
of perinatal HIV infection, gastritis, asthma), -44C 
(atopic dermatitis, chronic obstructive pulmonar 
disease, Crohn's disease, cancer, lepromatous leprosy) 
and -20 A/G (infections in cystic fibrosis) (gene RIF at 
www.ncbi.nlm.nih.gov; Prado-Montes de Oca, 2010). 
The variant -44C correlates with lower constitutive 
expression and -44G correlates with lower IFN-
gamma-dependent induction.  
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Figure 3. The 214 polymorphisms annotated in both strands of DEFB1 gene according to UCSC Genome Browser 
(www.genome.ucsc.edu, hg19, Feb 2009). Most polymorphisms are located in intron (black), fewer are located in UTRs (blue) and 
exons. Those polymorphisms located in exons could be either synonymous (green) or non-synonymous (red). 
 
This could explain the extremely rare heterozygote 
advantage in this region (Figuera et al., 2005; Prado 
Montes de Oca, 2010). 
Implicated in 
The 8p23.1 duplication syndrome 
Note 
Associate with variable phenotype that may include 
one or more of the following: developmental delay, 
mild dysmorphism and heart defects (Barber et al., 
2010). 
Cytogenetics 
The 8p23.1 duplication syndrome and copy number 
variation of the 8p23.1 defensin gene cluster are 
cytogenetically indistinguishable but distinct at the 
molecular level (Barber et al., 2010). 
Copy number variation of the 8p23.1 
defensin gene cluster 
Note 
From 1 to 12 copies of 8p23.1 defensin gene cluster are 
normally found per diploid genome (Hollox et al., 
2003). The null allele is very rare (allele frequency 
0.2%) (Hollox et al., 2008). Predisposition to Crohn's 
disease and sporadic prostate cancer is higher at low 
copy number (Huse et al., 2008) and to psoriasis at high 
copy number (Hollox, 2008). 
Oral squamous cell carcinoma (OSCC) 
Note 
DEFB1 basal expression is 50-fold lower in OSCC, and
inducibility is significantly reduced (Wenghoefer et al., 
2008). Genotypes in DEFB1 gene tend to loss of 
heterozygosity in OSCC (Joly et al., 2009). 
Malignant melanoma 
Note 
It was found weak evidence that genotype -44 GG in 
DEFB1 increases risk for malignant melanoma in a 
Spanish population (OR= 2.78, CI 95%= 0.88-8.82, 
p=0.08) (Fernandez et al., 2009). 
Prostate and renal cancers 
Note 
DEFB1 has been proposed as a tumor suppressor 
because it promotes cancer cells apoptosis and is absent 
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in most tumor samples (Sun et al., 2006; Bullard et al., 
2008). There is a marked down-regulation of DEFB1 in 
82% of prostate cancers and 90% of renal cell 
carcinomas (Donald et al., 2003) and this DEFB1 
downregulation is associated with malignancy 
(Wenghoefer et al., 2008; Pantelis et al., 2009). 
Furthermore, oncogene PAX2 binds to DEFB1 
promoter and suppresses its expression independent of 
p53 (Bose et al., 2009). Parvalbumin and DEFB1 
expression could be useful to differentiate papillary 
renal cell carcinoma (RCC) from conventional RCC 
(Young et al., 2003). 
Leukoplakia 
Note 
DEFB1 is downregulated 2.5 fold in leukoplakia but 
their role in the disease, if any, is unknown 
(Wenghoefer et al., 2008). 
Several allergic and infectious diseases 
Note 
For allergic and infectious diseases where DEFB1 is 
implicated see Prado Montes de Oca, 2010. 
To be noted 
Note 
Gene regulation of DEFB1 is not well known. More 
experimental data is needed to differentiate the 
constitutive from the inducible pathways (Kalus et al.,
2009; Prado Montes de Oca et al., 2009) in order to 
propose alternative therapies to diseases where DEFB1 
is implicated (Prado Montes de Oca, 2010). 
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